FOCUS ISSUE: ASPIRIN: STATE-OF-THE-ART PAPER
Aspirin Resistance and Atherothrombotic Disease
Peter J. Mason, MD, MPH*,
Alice K. Jacobs, MD, FACC and
Jane E. Freedman, MD, FACC
Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Manuscript received June 8, 2004;
revised manuscript received August 10, 2004,
accepted August 23, 2004.
* Reprint requests and correspondence: Dr. Peter J. Mason, Brigham and Womens Hospital, Division of Cardiovascular Medicine, 75 Francis Street, Boston, Massachusetts 02115. (Email: pjmason{at}partners.org).
Acute coronary syndromes and other manifestations of atherothrombotic disease are primarily caused by atherosclerotic plaque rupture or fissuring and subsequent occlusive or subocclusive thrombus formation. Platelets play a critical role in the pathophysiology of atherothrombotic disease, and aspirin is the most commonly used antiplatelet agent. Clinical trials have demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardial infarction, stroke, and cardiovascular death. Despite its proven benefit, the absolute risk of recurrent vascular events among patients taking aspirin remains relatively high, an estimated 8% to 18% after two years. Therapeutic resistance to aspirin might explain a portion of this risk. Although formal diagnostic criteria and a validated method of measurement are lacking, aspirin resistance may affect between 5% and 45% of the population. Given the prevalence of cardiovascular disease, the potential impact of aspirin resistance is large. Currently, however, there are many unanswered questions regarding the biological mechanism, diagnosis, population prevalence, clinical relevance, and optimal therapeutic intervention for aspirin resistance.
|
Abbreviations and Acronyms
| | ADP = adenosine diphosphate | | CAD = coronary artery disease | | COX = cyclooxygenase | | CRP = C-reactive protein | | MI = myocardial infarction | | NSAIDs = non-steroidal anti-inflammatory drugs | | PFA = platelet function analyzer | | PG = prostaglandin | | PGH2 = prostaglandin H2 | | PGI2 = endothelium-derived prostacyclin | | PURSUIT = Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy trial | | RPFA = rapid platelet function assay | | TX = thromboxane |
|
This article has been cited by other articles:

|
 |

|
 |
 
J. Fauler
Clinical pharmacology of antithrombotic drugs in coronary artery disease
Therapeutic Advances in Cardiovascular Disease,
December 1, 2009;
3(6):
465 - 478.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A R Muir, M F McMullin, C Patterson, and P P McKeown
Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease
Heart,
August 1, 2009;
95(15):
1225 - 1229.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Van de Werf
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Eur. Heart J.,
July 2, 2009;
30(14):
1695 - 1702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman and E. M. Hylek
Clopidogrel, Genetics, and Drug Responsiveness
N. Engl. J. Med.,
January 22, 2009;
360(4):
411 - 413.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. De Luca
Adjunctive antithrombotic therapy during primary percutaneous coronary intervention
Eur. Heart J. Suppl.,
December 1, 2008;
10(suppl_J):
J2 - J14.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Herrera-Galeano, D. M. Becker, A. F. Wilson, L. R. Yanek, P. Bray, D. Vaidya, N. Faraday, and L. C. Becker
A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet Aggregability
Arterioscler Thromb Vasc Biol,
August 1, 2008;
28(8):
1484 - 1490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. H. Hennekens and S. Borzak
Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2008;
13(1):
41 - 50.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman
Heritability, Platelet Function, and Aspirin: A Link Established but Cause Unknown
Circulation,
May 15, 2007;
115(19):
2468 - 2470.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P Dorsch, J. S. Lee, D. R Lynch, S. P Dunn, J. E Rodgers, T. Schwartz, E. Colby, D. Montague, and S. S Smyth
Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction
Ann. Pharmacother.,
May 1, 2007;
41(5):
737 - 741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Undas, K. E. Brummel-Ziedins, and K. G. Mann
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
Blood,
March 15, 2007;
109(6):
2285 - 2292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Mason, A. K. Jacobs, and J. E. Freedman
Reply
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
847 - 847.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. O. Maree, H. Jneid, and D. J. Fitzgerald
Aspirin Resistance and Atherothrombotic Disease
J. Am. Coll. Cardiol.,
August 15, 2006;
48(4):
846 - 847.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
386 - 395.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Freedman
The Aspirin Resistance Controversy: Clinical Entity or Platelet Heterogeneity?
Circulation,
June 27, 2006;
113(25):
2865 - 2867.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Hillman
Platelet Aspirin Resistance Detection and Validation
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2565 - 2565.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Leineweber, D. Bose, M. Vogelsang, M. Haude, R. Erbel, and G. Heusch
Intense Vasoconstriction in Response to Aspirate From Stented Saphenous Vein Aortocoronary Bypass Grafts
J. Am. Coll. Cardiol.,
March 7, 2006;
47(5):
981 - 986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease
Diabetes,
March 1, 2006;
55(3):
780 - 784.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|